aspirin has been researched along with Ovarian Neoplasms in 78 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Regular aspirin use may decrease cancer risk by reducing chronic inflammation." | 9.20 | Association between Regular Aspirin Use and Circulating Markers of Inflammation: A Study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. ( Chaturvedi, AK; Hildesheim, A; Katki, HA; Kemp, TJ; Lang Kuhs, KA; Loftfield, E; Pinto, LA; Purdue, MP; Safaeian, M; Shiels, MS; Trabert, B; Wentzensen, N, 2015) |
| "Aspirin use was associated with a reduced risk of ovarian cancer, especially among daily users of low-dose aspirin." | 6.50 | Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. ( Anton-Culver, H; Bandera, EV; Berchuck, A; Brinton, LA; Chandran, U; Cramer, DW; Doherty, JA; Gayther, SA; Gentry-Maharaj, A; Goode, EL; Goodman, MT; Hogdall, E; Jensen, A; Jordan, SJ; King, MG; Kjær, SK; Lo-Ciganic, WH; Lurie, G; Menon, U; Murphy, MA; Nagle, CM; Ness, RB; Olson, S; Pearce, CL; Pike, MC; Poole, EM; Ramus, SJ; Risch, HA; Rossing, MA; Schildkraut, JM; Terry, KL; Trabert, B; Vitonis, A; Webb, PM; Wentzensen, N; Wu, AH; Ziogas, A, 2014) |
| "Regular aspirin use may decrease cancer risk by reducing chronic inflammation." | 5.20 | Association between Regular Aspirin Use and Circulating Markers of Inflammation: A Study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. ( Chaturvedi, AK; Hildesheim, A; Katki, HA; Kemp, TJ; Lang Kuhs, KA; Loftfield, E; Pinto, LA; Purdue, MP; Safaeian, M; Shiels, MS; Trabert, B; Wentzensen, N, 2015) |
| "Evidence clearly shows a chemopreventive effect for aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) on colorectal cancer and probably other cancer types; however, data on the risk-benefit profile for cancer prevention are insufficient and no definitive recommendations can be made." | 4.85 | Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. ( Baron, JA; Brown, PH; Burn, J; Cuzick, J; Greenwald, P; Jankowski, J; La Vecchia, C; Meyskens, F; Otto, F; Senn, HJ; Thun, M, 2009) |
| "To investigate the association of aspirin use with risk of all-cause, any cancer, gastrointestinal (GI) cancer, and colorectal cancer (CRC) mortality among older adults and to perform an exploratory analysis of the association of aspirin use with mortality stratified by BMI." | 3.91 | Association of Aspirin Use With Mortality Risk Among Older Adult Participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. ( Cao, Y; Chan, AT; Loomans-Kropp, HA; Pinsky, P; Umar, A, 2019) |
| "Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% CIs for associations of aspirin, nonaspirin NSAIDs, and acetaminophen with risk of epithelial ovarian cancer." | 3.88 | Association of Analgesic Use With Risk of Ovarian Cancer in the Nurses' Health Studies. ( Barnard, ME; Curhan, GC; Eliassen, AH; Poole, EM; Rosner, BA; Terry, KL; Tworoger, SS, 2018) |
| "Nine cohort studies from the Ovarian Cancer Cohort Consortium (n = 2,600 cases) and eight case-control studies from the Ovarian Cancer Association Consortium (n = 5,726 cases) were included." | 2.82 | Modification of the Association Between Frequent Aspirin Use and Ovarian Cancer Risk: A Meta-Analysis Using Individual-Level Data From Two Ovarian Cancer Consortia. ( Anton-Culver, H; Berchuck, A; Chan, AT; Doherty, JA; Fortner, RT; Goodman, MT; Harris, HR; Hartge, P; Hurwitz, LM; Jordan, SJ; Lacey, JV; Menon, U; Modugno, F; Moysich, KB; O'Brien, KM; Patel, AV; Pearce, CL; Peters, U; Prizment, A; Ramus, SJ; Robien, K; Sandler, DP; Schildkraut, JM; Shvetsov, YB; Teras, LR; Townsend, MK; Trabert, B; Tworoger, SS; Webb, PM; Wentzensen, N; White, E; Wu, AH; Ziogas, A, 2022) |
| "Ovarian cancer is usually diagnosed at an advanced stage when five-year relative survival is <50%." | 2.66 | Common medications and survival in women with ovarian cancer: A systematic review and meta-analysis. ( Dixon-Suen, S; Jordan, SJ; Majidi, A; Na, R; Webb, PM, 2020) |
| "Thus our data suggest that residual ovarian cancer is accompanied by increased production of PG1(2) and TxA2, and that prostaglandins have no role in the acute side effects of cancer chemotherapy." | 2.65 | Prostacyclin and thromboxane in ovarian cancer: effect of cytostatics and prostaglandin synthesis inhibitors. ( Kauppila, A; Viinikka, L; Ylikorkala, O, 1983) |
| "Pooling individual-level data from 12 Ovarian Cancer Association Consortium studies, we evaluated the association between self-reported, pre-diagnosis use of common analgesics and overall/progression-free/disease-specific survival among 7694 women with invasive epithelial ovarian cancer (4273 deaths)." | 2.55 | Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. ( Anton-Culver, H; Bandera, EV; Beeghly-Fadiel, A; Berchuck, A; Cramer, DW; deFazio, A; Dixon, SC; Doherty, JA; Edwards, RP; Gayther, SA; Gentry-Maharaj, A; Goodman, MT; Høgdall, E; Jensen, A; Kjær, SK; Menon, U; Modugno, F; Moysich, KB; Nagle, CM; Ness, RB; Paddock, LE; Pearce, CL; Pike, MC; Poole, EM; Ramus, SJ; Risch, HA; Rossing, MA; Schildkraut, JM; Terry, KL; Trabert, B; Webb, PM; Wentzensen, N; Wicklund, KG; Wu, AH; Ziogas, A, 2017) |
| "Aspirin use was associated with a reduced risk of ovarian cancer, especially among daily users of low-dose aspirin." | 2.50 | Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. ( Anton-Culver, H; Bandera, EV; Berchuck, A; Brinton, LA; Chandran, U; Cramer, DW; Doherty, JA; Gayther, SA; Gentry-Maharaj, A; Goode, EL; Goodman, MT; Hogdall, E; Jensen, A; Jordan, SJ; King, MG; Kjær, SK; Lo-Ciganic, WH; Lurie, G; Menon, U; Murphy, MA; Nagle, CM; Ness, RB; Olson, S; Pearce, CL; Pike, MC; Poole, EM; Ramus, SJ; Risch, HA; Rossing, MA; Schildkraut, JM; Terry, KL; Trabert, B; Vitonis, A; Webb, PM; Wentzensen, N; Wu, AH; Ziogas, A, 2014) |
| "However, the risk of invasive ovarian cancer was significantly reduced with use of aspirin (RR 0." | 2.49 | Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies. ( Andersen, KK; Baandrup, L; Christensen, J; Faber, MT; Friis, S; Jensen, A; Kjaer, SK, 2013) |
| "A recent meta-analysis reported a RR of breast cancer for aspirin use of 0." | 2.41 | Aspirin and cancer risk: an update to 2001. ( Bosetti, C; Gallus, S; La Vecchia, C, 2002) |
| "Most women with ovarian cancer (OC) are diagnosed with advanced disease." | 1.91 | Common analgesics and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) Study. ( DeFazio, A; Friedlander, M; Grant, P; Jordan, SJ; Majidi, A; Na, R; Obermair, A; Webb, PM, 2023) |
| "The 13% reduction in ovarian cancer risk associated with frequent aspirin use (OR, 0." | 1.91 | Association of Frequent Aspirin Use With Ovarian Cancer Risk According to Genetic Susceptibility. ( Anton-Culver, H; Berchuck, A; Doherty, JA; Goodman, MT; Harris, HR; Hurwitz, LM; Jordan, SJ; Menon, U; Modugno, F; Moysich, KB; Pearce, CL; Pharoah, PDP; Ramus, SJ; Schildkraut, JM; Shvetsov, YB; Trabert, B; Tworoger, SS; Webb, PM; Wentzensen, N; Wu, AH; Ziogas, A, 2023) |
| "Aspirin use has been associated with reduced ovarian cancer risk, yet the underlying biological mechanisms are not fully understood." | 1.91 | Associations between prediagnostic aspirin use and ovarian tumor gene expression. ( Cleveland, JL; Conejo-Garcia, J; Fridley, BL; Hecht, JL; Sasamoto, N; Stewart, PA; Terry, KL; Thompson, ZJ; Tworoger, SS; Wang, T; Yoder, SJ, 2023) |
| "Using in vivo model systems of ovarian cancer, we found that aspirin-PC significantly reduced ovarian cancer growth by 50% to 90% (depending on the ovarian cell line)." | 1.43 | Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer. ( Bottsford-Miller, JN; Dial, EJ; Dorniak, PL; Fang, D; Filant, J; Haemmerle, M; Hansen, JM; Hatakeyama, H; Hu, W; Huang, Y; Lichtenberger, LM; Lyons, Y; Pradeep, S; Previs, RA; Shen, F; Sood, AK; Taylor, M; Wagner, MJ, 2016) |
| "99) and with long-term use (≥5 years) of low-dose aspirin (OR = 0." | 1.42 | Low-dose aspirin use and the risk of ovarian cancer in Denmark. ( Baandrup, L; Dehlendorff, C; Friis, S; Kjaer, SK; Olsen, JH, 2015) |
| "Ovarian cancer has a poor prognosis because the disease in the majority of patients is diagnosed at an advanced stage as a result of nonspecific symptoms and lack of efficient screening methods." | 1.42 | Drugs with potential chemopreventive properties in relation to epithelial ovarian cancer--a nationwide case-control study. ( Baandrup, L, 2015) |
| "It is unknown why different ovarian cancers have different metastatic phenotypes." | 1.42 | Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion. ( Cooke, NM; Kenny, D; O'Leary, J; Sheils, O; Spillane, CD, 2015) |
| "Aspirin use was associated with a marginally significant reduction in incidence of VTEs within 2 years of diagnosis, HR 0." | 1.40 | Statins, aspirin and risk of thromboembolic events in ovarian cancer patients. ( Lavie, O; Leviov, M; Rennert, G; Rennert, HS; Sagi, S; Shai, A, 2014) |
| "Risk reductions of ovarian cancer were observed with use of aspirin or selective cyclooxygenase-2 inhibitors." | 1.38 | Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or acetaminophen and risk of ovarian cancer. ( Bunker, CH; Edwards, RP; Lo-Ciganic, WH; Moysich, KB; Ness, RB; Zgibor, JC, 2012) |
| "We included 756 women with epithelial ovarian cancer and 1564 randomly selected control women aged 35-79 years." | 1.38 | Use of analgesic drugs and risk of ovarian cancer: results from a Danish case-control study. ( Ammundsen, HB; Blaakaer, J; Faber, MT; Høgdall, C; Høgdall, E; Jensen, A; Kjaer, SK, 2012) |
| "VEGF may play a role in ovarian cancer progression in the hen and the proliferation of ascites cells can be decreased by targeting the COX-1 but not COX-2 pathway." | 1.35 | VEGF expression and the effect of NSAIDs on ascites cell proliferation in the hen model of ovarian cancer. ( Giles, JR; Johnson, PA; Urick, ME, 2008) |
| "Aspirin treatment may inhibit the progression of ovarian cancer in the hen and egg production may be used to identify hens with early stages of the disease." | 1.35 | Dietary aspirin decreases the stage of ovarian cancer in the hen. ( Giles, JR; Johnson, PA; Urick, ME, 2009) |
| "Analgesic use may reduce ovarian cancer risk, possibly through antiinflammatory or antigonadotropic effects." | 1.35 | Analgesic drug use and risk of epithelial ovarian cancer. ( Cushing-Haugen, KL; Hannibal, CG; Rossing, MA; Wicklund, KG, 2008) |
| " The authors did not observe a dose-response relation with increased frequency or duration of regular use of any of these medications and ovarian cancer incidence." | 1.35 | Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts. ( Cramer, DW; Hankinson, SE; Pinheiro, SP; Rosner, BA; Tworoger, SS, 2009) |
| "The underlying causes of epithelial ovarian cancer (EOC) are unclear, and treatment options for patients with advanced disease are limited." | 1.34 | Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer. ( Chakrabarty, A; Daikoku, T; Dey, SK; Dubois, RN; Khabele, D; Morrow, JD; Orsulic, S; Tranguch, S; Wang, D, 2007) |
| " Xenografted nude mice models of human ovarian cancer were established, and then randomly allocated to treatment or control group, which was administered with either Celecoxib at the dosage of 10, 25, 50 mg/kg or distilled water alone (control) orally daily for 56 d." | 1.34 | [The growth inhibitory effect of non-steroid anti-inflammatory drugs on ovarian cancer]. ( Liu, XQ; Lou, JY; Luo, FM; Peng, ZL; Wang, HJ; Yang, KX, 2007) |
| "Ovarian cancer is a gynecological malignancy that is commonly treated by cytoreductive surgery followed by cisplatin treatment." | 1.33 | Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin. ( Bratasz, A; Ignarro, LJ; Kuppusamy, P; Parinandi, NL; Sridhar, R; Weir, NM; Zweier, JL, 2006) |
| "Aspirin might exert its anti-metastasis effects on ovarian cancer by affecting metastasis-associated gene expression." | 1.32 | Effects of aspirin on metastasis-associated gene expression detected by cDNA microarray. ( Gao, XQ; Han, JX; Huang, HN; Huang, HY; Song, CZ; Yan, S, 2004) |
| "In a prospective study, we evaluated ovarian cancer risk associated with self-reported use of medications that influence inflammation or gonadotropin levels." | 1.32 | Medication use and risk of ovarian carcinoma: a prospective study. ( Hartge, P; Lacey, JV; Schairer, C; Schatzkin, A; Sherman, ME, 2004) |
| "Aspirin use was not associated with ovarian cancer risk overall (RR for users compared with nonusers, 1." | 1.31 | Aspirin, other NSAIDs, and ovarian cancer risk (United States). ( Colditz, GA; Fairfield, KM; Fuchs, CS; Hankinson, SE; Hunter, DJ, 2002) |
| "Aspirin users were not at reduced risk of ovarian cancer compared with nonusers (adjusted OR, 1." | 1.31 | Regular use of analgesic drugs and ovarian cancer risk. ( Menezes, RJ; Mettlin, C; Moysich, KB; Natarajan, N; Piver, MS; Swede, H, 2001) |
| "Apoptosis was observed in primary ovarian cancer cell culture treated with COX-2 inhibitor." | 1.31 | Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. ( Barnes, MN; Grizzle, WE; Myers, RB; Oelschlager, DK; Partridge, EE; Rodríguez-Burford, C; Talley, LI, 2002) |
| "The odds ratio for risk of ovarian cancer for aspirin use was 0." | 1.30 | Over-the-counter analgesics and risk of ovarian cancer. ( Bohlke, K; Cramer, DW; Greenberg, ER; Harlow, BL; Titus-Ernstoff, L; Welch, WR, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.28) | 18.7374 |
| 1990's | 1 (1.28) | 18.2507 |
| 2000's | 31 (39.74) | 29.6817 |
| 2010's | 34 (43.59) | 24.3611 |
| 2020's | 11 (14.10) | 2.80 |
| Authors | Studies |
|---|---|
| Hurwitz, LM | 3 |
| Townsend, MK | 1 |
| Jordan, SJ | 5 |
| Patel, AV | 2 |
| Teras, LR | 1 |
| Lacey, JV | 3 |
| Doherty, JA | 4 |
| Harris, HR | 2 |
| Goodman, MT | 4 |
| Shvetsov, YB | 2 |
| Modugno, F | 3 |
| Moysich, KB | 6 |
| Robien, K | 2 |
| Prizment, A | 3 |
| Schildkraut, JM | 4 |
| Berchuck, A | 4 |
| Fortner, RT | 2 |
| Chan, AT | 2 |
| Wentzensen, N | 6 |
| Hartge, P | 3 |
| Sandler, DP | 2 |
| O'Brien, KM | 1 |
| Anton-Culver, H | 4 |
| Ziogas, A | 4 |
| Menon, U | 4 |
| Ramus, SJ | 4 |
| Pearce, CL | 4 |
| Wu, AH | 4 |
| White, E | 2 |
| Peters, U | 2 |
| Webb, PM | 9 |
| Tworoger, SS | 6 |
| Trabert, B | 7 |
| Sinha, BK | 1 |
| Tokar, EJ | 1 |
| Bortner, CD | 1 |
| Majidi, A | 2 |
| Na, R | 2 |
| DeFazio, A | 3 |
| Obermair, A | 1 |
| Friedlander, M | 1 |
| Grant, P | 1 |
| Pharoah, PDP | 1 |
| Loomans-Kropp, HA | 2 |
| Umar, A | 2 |
| Sasamoto, N | 1 |
| Stewart, PA | 1 |
| Wang, T | 2 |
| Thompson, ZJ | 1 |
| Yoder, SJ | 1 |
| Hecht, JL | 1 |
| Cleveland, JL | 1 |
| Conejo-Garcia, J | 1 |
| Fridley, BL | 1 |
| Terry, KL | 4 |
| Pinsky, P | 1 |
| Cao, Y | 1 |
| Dixon-Suen, S | 1 |
| Meiser, B | 1 |
| Kaur, R | 1 |
| Kirk, J | 1 |
| Morrow, A | 1 |
| Peate, M | 1 |
| Wong, WKT | 1 |
| McPike, E | 1 |
| Cops, E | 1 |
| Dowson, C | 1 |
| Austin, R | 1 |
| Fine, M | 1 |
| Thrupp, L | 1 |
| Ward, R | 1 |
| Macrae, F | 1 |
| Hiller, JE | 1 |
| Trainer, AH | 1 |
| Mitchell, G | 1 |
| Pinsky, PF | 1 |
| Huang, WY | 1 |
| Freedman, ND | 1 |
| Patel, S | 1 |
| Sanborn, D | 1 |
| Issa, M | 1 |
| Macciò, A | 1 |
| Oppi, S | 1 |
| Madeddu, C | 1 |
| Dixon, SC | 1 |
| Nagle, CM | 4 |
| Beeghly-Fadiel, A | 1 |
| Risch, HA | 2 |
| Rossing, MA | 3 |
| Wicklund, KG | 2 |
| Ness, RB | 3 |
| Edwards, RP | 2 |
| Jensen, A | 4 |
| Kjær, SK | 2 |
| Høgdall, E | 2 |
| Cramer, DW | 4 |
| Poole, EM | 4 |
| Bandera, EV | 2 |
| Paddock, LE | 1 |
| Gayther, SA | 2 |
| Gentry-Maharaj, A | 2 |
| Pike, MC | 2 |
| Verdoodt, F | 1 |
| Kjaer, SK | 4 |
| Friis, S | 3 |
| Visvanathan, K | 1 |
| Adami, HO | 1 |
| Anderson, GL | 1 |
| Brasky, TM | 1 |
| Brinton, LA | 2 |
| Gaudet, M | 1 |
| Hoffman-Bolton, J | 1 |
| Jones, M | 1 |
| Larsson, SC | 1 |
| Mackenzie, GG | 1 |
| Schouten, LJ | 1 |
| O'Brien, K | 1 |
| Setiawan, VW | 1 |
| Swerdlow, A | 1 |
| van den Brandt, PA | 1 |
| Weiderpass, E | 1 |
| Wilkens, LR | 1 |
| Wolk, A | 1 |
| Surnar, B | 1 |
| Kolishetti, N | 1 |
| Basu, U | 1 |
| Ahmad, A | 1 |
| Goka, E | 1 |
| Marples, B | 1 |
| Kolb, D | 1 |
| Lippman, ME | 1 |
| Dhar, S | 1 |
| Barnard, ME | 1 |
| Curhan, GC | 1 |
| Eliassen, AH | 1 |
| Rosner, BA | 2 |
| Rosenberg, K | 1 |
| Mechcatie, E | 1 |
| Minlikeeva, AN | 1 |
| Tsoref, D | 1 |
| Panzarella, T | 1 |
| Oza, A | 1 |
| Lo-Ciganic, WH | 2 |
| Murphy, MA | 1 |
| Goode, EL | 1 |
| Lurie, G | 1 |
| Hogdall, E | 1 |
| Vitonis, A | 1 |
| Olson, S | 1 |
| King, MG | 1 |
| Chandran, U | 1 |
| Errico, A | 1 |
| Shai, A | 1 |
| Rennert, HS | 1 |
| Rennert, G | 1 |
| Sagi, S | 1 |
| Leviov, M | 1 |
| Lavie, O | 1 |
| Alosh, M | 1 |
| Huque, MF | 1 |
| Koch, GG | 1 |
| Baandrup, L | 3 |
| Olsen, JH | 1 |
| Dehlendorff, C | 1 |
| Ibiebele, TI | 1 |
| Protani, MM | 1 |
| Lang Kuhs, KA | 1 |
| Hildesheim, A | 1 |
| Kemp, TJ | 1 |
| Purdue, MP | 1 |
| Katki, HA | 1 |
| Pinto, LA | 1 |
| Loftfield, E | 1 |
| Safaeian, M | 1 |
| Chaturvedi, AK | 1 |
| Shiels, MS | 1 |
| Lheureux, S | 1 |
| Karakasis, K | 1 |
| Oza, AM | 1 |
| Zhou, L | 1 |
| Duan, X | 1 |
| Zeng, S | 1 |
| Men, K | 1 |
| Zhang, X | 1 |
| Yang, L | 1 |
| Li, X | 1 |
| Cooke, NM | 1 |
| Spillane, CD | 1 |
| Sheils, O | 1 |
| O'Leary, J | 1 |
| Kenny, D | 1 |
| Zhang, D | 1 |
| Bai, B | 1 |
| Xi, Y | 1 |
| Zhao, Y | 1 |
| Essandoh, MK | 1 |
| Dalia, AA | 1 |
| George, BS | 1 |
| Flores, AS | 1 |
| Otey, AJ | 1 |
| Kirtane, AJ | 1 |
| Broderick, TM | 1 |
| Rao, SV | 1 |
| Huang, Y | 1 |
| Lichtenberger, LM | 1 |
| Taylor, M | 1 |
| Bottsford-Miller, JN | 1 |
| Haemmerle, M | 1 |
| Wagner, MJ | 1 |
| Lyons, Y | 1 |
| Pradeep, S | 1 |
| Hu, W | 1 |
| Previs, RA | 1 |
| Hansen, JM | 1 |
| Fang, D | 1 |
| Dorniak, PL | 1 |
| Filant, J | 1 |
| Dial, EJ | 1 |
| Shen, F | 1 |
| Hatakeyama, H | 1 |
| Sood, AK | 1 |
| Vaughan, LE | 1 |
| Blair, CK | 1 |
| Thomas, W | 1 |
| Anderson, KE | 1 |
| Chiyoda, T | 1 |
| Hart, PC | 1 |
| Eckert, MA | 1 |
| McGregor, SM | 1 |
| Lastra, RR | 1 |
| Hamamoto, R | 1 |
| Nakamura, Y | 1 |
| Yamada, SD | 1 |
| Olopade, OI | 1 |
| Lengyel, E | 1 |
| Romero, IL | 1 |
| Sonnemann, J | 1 |
| Hüls, I | 1 |
| Sigler, M | 1 |
| Palani, CD | 1 |
| Hong, le TT | 1 |
| Völker, U | 1 |
| Kroemer, HK | 1 |
| Beck, JF | 1 |
| Urick, ME | 2 |
| Giles, JR | 2 |
| Johnson, PA | 2 |
| Breslow, RG | 1 |
| Caiado, J | 1 |
| Castells, MC | 1 |
| Pinheiro, SP | 1 |
| Hankinson, SE | 2 |
| Cuzick, J | 1 |
| Otto, F | 1 |
| Baron, JA | 1 |
| Brown, PH | 1 |
| Burn, J | 1 |
| Greenwald, P | 1 |
| Jankowski, J | 1 |
| La Vecchia, C | 3 |
| Meyskens, F | 1 |
| Senn, HJ | 1 |
| Thun, M | 1 |
| Uddin, S | 1 |
| Ahmed, M | 1 |
| Hussain, A | 1 |
| Assad, L | 1 |
| Al-Dayel, F | 1 |
| Bavi, P | 1 |
| Al-Kuraya, KS | 1 |
| Munkarah, A | 1 |
| Son, DS | 1 |
| Wilson, AJ | 1 |
| Parl, AK | 1 |
| Khabele, D | 2 |
| Graham, DF | 1 |
| Hadlow, N | 1 |
| Tsokos, N | 1 |
| Oates, R | 1 |
| Jakubowska-Mućka, A | 1 |
| Sieńko, J | 1 |
| Switaj, T | 1 |
| Gołab, J | 1 |
| Lasek, W | 1 |
| Zgibor, JC | 1 |
| Bunker, CH | 1 |
| Ammundsen, HB | 1 |
| Faber, MT | 2 |
| Blaakaer, J | 1 |
| Høgdall, C | 1 |
| Christensen, J | 1 |
| Andersen, KK | 1 |
| Fairfield, KM | 1 |
| Hunter, DJ | 1 |
| Fuchs, CS | 1 |
| Colditz, GA | 1 |
| Drake, JG | 1 |
| Becker, JL | 1 |
| Bosetti, C | 1 |
| Gallus, S | 2 |
| Munkarah, AR | 1 |
| Genhai, Z | 1 |
| Morris, R | 1 |
| Baker, VV | 1 |
| Deppe, G | 1 |
| Diamond, MP | 1 |
| Saed, GM | 1 |
| Rodríguez-Burford, C | 2 |
| Oelschlager, DK | 2 |
| Talley, LI | 2 |
| Barnes, MN | 2 |
| Partridge, EE | 2 |
| Grizzle, WE | 2 |
| Sherman, ME | 1 |
| Schatzkin, A | 1 |
| Schairer, C | 1 |
| Din, FV | 1 |
| Dunlop, MG | 1 |
| Stark, LA | 1 |
| Gao, XQ | 1 |
| Han, JX | 1 |
| Huang, HY | 1 |
| Yan, S | 1 |
| Song, CZ | 1 |
| Huang, HN | 1 |
| Bonovas, S | 1 |
| Filioussi, K | 1 |
| Sitaras, NM | 1 |
| Kang, S | 1 |
| Luo, R | 1 |
| Smicun, Y | 1 |
| Fishman, DA | 1 |
| Meng, Y | 1 |
| Salman, MC | 1 |
| Ayhan, A | 1 |
| Crew, KD | 1 |
| Neugut, AI | 1 |
| Bratasz, A | 3 |
| Weir, NM | 1 |
| Parinandi, NL | 1 |
| Zweier, JL | 1 |
| Sridhar, R | 1 |
| Ignarro, LJ | 3 |
| Kuppusamy, P | 3 |
| Daikoku, T | 1 |
| Tranguch, S | 1 |
| Chakrabarty, A | 1 |
| Wang, D | 1 |
| Orsulic, S | 1 |
| Morrow, JD | 1 |
| Dubois, RN | 1 |
| Dey, SK | 1 |
| Wang, HJ | 1 |
| Peng, ZL | 1 |
| Liu, XQ | 1 |
| Yang, KX | 1 |
| Lou, JY | 1 |
| Luo, FM | 1 |
| Merritt, MA | 1 |
| Green, AC | 1 |
| Xin, B | 1 |
| Yokoyama, Y | 1 |
| Shigeto, T | 1 |
| Mizunuma, H | 1 |
| Selvendiran, K | 2 |
| Tong, L | 1 |
| Robles-Díaz, G | 1 |
| Fastag, D | 1 |
| Wasowicz, T | 1 |
| Bobko, A | 1 |
| Khramtsov, VV | 1 |
| Hannibal, CG | 1 |
| Cushing-Haugen, KL | 1 |
| Ylikorkala, O | 1 |
| Kauppila, A | 1 |
| Viinikka, L | 1 |
| Harlow, BL | 1 |
| Titus-Ernstoff, L | 1 |
| Bohlke, K | 1 |
| Welch, WR | 1 |
| Greenberg, ER | 1 |
| Tavani, A | 1 |
| Conti, E | 1 |
| Montella, M | 1 |
| Franceschi, S | 1 |
| Mettlin, C | 1 |
| Piver, MS | 1 |
| Natarajan, N | 1 |
| Menezes, RJ | 1 |
| Swede, H | 1 |
| Akhmedkhanov, A | 1 |
| Toniolo, P | 1 |
| Zeleniuch-Jacquotte, A | 1 |
| Kato, I | 1 |
| Koenig, KL | 1 |
| Shore, RE | 1 |
| Myers, RB | 1 |
13 reviews available for aspirin and Ovarian Neoplasms
| Article | Year |
|---|---|
Modification of the Association Between Frequent Aspirin Use and Ovarian Cancer Risk: A Meta-Analysis Using Individual-Level Data From Two Ovarian Cancer Consortia.
Topics: Aspirin; Case-Control Studies; Endometriosis; Female; Humans; Ovarian Neoplasms; Risk Factors | 2022 |
Modification of the Association Between Frequent Aspirin Use and Ovarian Cancer Risk: A Meta-Analysis Using Individual-Level Data From Two Ovarian Cancer Consortia.
Topics: Aspirin; Case-Control Studies; Endometriosis; Female; Humans; Ovarian Neoplasms; Risk Factors | 2022 |
Common medications and survival in women with ovarian cancer: A systematic review and meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Hydroxymethylglutaryl-CoA Reductas | 2020 |
Common medications and survival in women with ovarian cancer: A systematic review and meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Hydroxymethylglutaryl-CoA Reductas | 2020 |
COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied?
Topics: Adrenal Cortex Hormones; Aspirin; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; COVID-19 | 2021 |
COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied?
Topics: Adrenal Cortex Hormones; Aspirin; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; COVID-19 | 2021 |
Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium.
Topics: Acetaminophen; Adult; Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Ag | 2017 |
Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium.
Topics: Acetaminophen; Adult; Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Ag | 2017 |
Influence of aspirin and non-aspirin NSAID use on ovarian and endometrial cancer: Summary of epidemiologic evidence of cancer risk and prognosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Endometrial Neoplasms; Female; Humans; Ovarian Neo | 2017 |
Influence of aspirin and non-aspirin NSAID use on ovarian and endometrial cancer: Summary of epidemiologic evidence of cancer risk and prognosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Endometrial Neoplasms; Female; Humans; Ovarian Neo | 2017 |
Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Australia; | 2014 |
Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Australia; | 2014 |
Is aspirin use associated with a decreased risk of ovarian cancer? A systematic review and meta-analysis of observational studies with dose-response analysis.
Topics: Aspirin; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Observational Studies as | 2016 |
Is aspirin use associated with a decreased risk of ovarian cancer? A systematic review and meta-analysis of observational studies with dose-response analysis.
Topics: Aspirin; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Observational Studies as | 2016 |
Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Colorectal Neoplasms; Digestive | 2009 |
Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Colorectal Neoplasms; Digestive | 2009 |
Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Confidence Intervals; Fem | 2013 |
Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Confidence Intervals; Fem | 2013 |
Aspirin and cancer risk: an update to 2001.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Case-Control Studies; Cohort Stu | 2002 |
Aspirin and cancer risk: an update to 2001.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Case-Control Studies; Cohort Stu | 2002 |
Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Cohort Studies; Female; Huma | 2005 |
Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Cohort Studies; Female; Huma | 2005 |
Aspirin and NSAIDs: effects in breast and ovarian cancers.
Topics: Acetaminophen; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Femal | 2006 |
Aspirin and NSAIDs: effects in breast and ovarian cancers.
Topics: Acetaminophen; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Femal | 2006 |
[Cancer of the pancreas. Epidemiology and risk factors].
Topics: Adenomatous Polyposis Coli; Age Factors; Aged; Aspirin; Breast Neoplasms; Diabetes Mellitus, Type 2; | 2007 |
[Cancer of the pancreas. Epidemiology and risk factors].
Topics: Adenomatous Polyposis Coli; Age Factors; Aged; Aspirin; Breast Neoplasms; Diabetes Mellitus, Type 2; | 2007 |
5 trials available for aspirin and Ovarian Neoplasms
| Article | Year |
|---|---|
Analysis of Body Mass Index in Early and Middle Adulthood and Estimated Risk of Gastrointestinal Cancer.
Topics: Adult; Aspirin; Body Mass Index; Colorectal Neoplasms; Female; Gastrointestinal Neoplasms; Humans; M | 2023 |
Analysis of Body Mass Index in Early and Middle Adulthood and Estimated Risk of Gastrointestinal Cancer.
Topics: Adult; Aspirin; Body Mass Index; Colorectal Neoplasms; Female; Gastrointestinal Neoplasms; Humans; M | 2023 |
Aspirin use and ovarian cancer risk using extended follow-up of the PLCO Cancer Screening Trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Early Detection of Cancer; Female; Humans; O | 2020 |
Aspirin use and ovarian cancer risk using extended follow-up of the PLCO Cancer Screening Trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Early Detection of Cancer; Female; Humans; O | 2020 |
Association between Regular Aspirin Use and Circulating Markers of Inflammation: A Study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Colorectal Neoplasms; Early Dete | 2015 |
Association between Regular Aspirin Use and Circulating Markers of Inflammation: A Study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Colorectal Neoplasms; Early Dete | 2015 |
Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization.
Topics: Acetates; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agent | 2009 |
Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization.
Topics: Acetates; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agent | 2009 |
Prostacyclin and thromboxane in ovarian cancer: effect of cytostatics and prostaglandin synthesis inhibitors.
Topics: 6-Ketoprostaglandin F1 alpha; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Epoprostenol; | 1983 |
Prostacyclin and thromboxane in ovarian cancer: effect of cytostatics and prostaglandin synthesis inhibitors.
Topics: 6-Ketoprostaglandin F1 alpha; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Epoprostenol; | 1983 |
60 other studies available for aspirin and Ovarian Neoplasms
| Article | Year |
|---|---|
Molecular Mechanisms of Cytotoxicity of NCX4040, the Non-Steroidal Anti-Inflammatory NO-Donor, in Human Ovarian Cancer Cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Carcinoma, Ovarian Epitheli | 2022 |
Molecular Mechanisms of Cytotoxicity of NCX4040, the Non-Steroidal Anti-Inflammatory NO-Donor, in Human Ovarian Cancer Cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Carcinoma, Ovarian Epitheli | 2022 |
Common analgesics and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) Study.
Topics: Acetaminophen; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Australia; Female; Huma | 2023 |
Common analgesics and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) Study.
Topics: Acetaminophen; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Australia; Female; Huma | 2023 |
Association of Frequent Aspirin Use With Ovarian Cancer Risk According to Genetic Susceptibility.
Topics: Aged; Aspirin; Carcinoma, Ovarian Epithelial; Female; Genetic Predisposition to Disease; Humans; Log | 2023 |
Association of Frequent Aspirin Use With Ovarian Cancer Risk According to Genetic Susceptibility.
Topics: Aged; Aspirin; Carcinoma, Ovarian Epithelial; Female; Genetic Predisposition to Disease; Humans; Log | 2023 |
Associations between prediagnostic aspirin use and ovarian tumor gene expression.
Topics: Aspirin; Case-Control Studies; Estrogens; Female; Gene Expression; Humans; Ovarian Neoplasms | 2023 |
Associations between prediagnostic aspirin use and ovarian tumor gene expression.
Topics: Aspirin; Case-Control Studies; Estrogens; Female; Gene Expression; Humans; Ovarian Neoplasms | 2023 |
Association of Aspirin Use With Mortality Risk Among Older Adult Participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Topics: Aged; Aspirin; Body Mass Index; Clinical Trials as Topic; Cohort Studies; Colorectal Neoplasms; Fema | 2019 |
Association of Aspirin Use With Mortality Risk Among Older Adult Participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Topics: Aged; Aspirin; Body Mass Index; Clinical Trials as Topic; Cohort Studies; Colorectal Neoplasms; Fema | 2019 |
Evaluation of implementation of risk management guidelines for carriers of pathogenic variants in mismatch repair genes: a nationwide audit of familial cancer clinics.
Topics: Adult; Anticarcinogenic Agents; Aspirin; Colonoscopy; Colorectal Neoplasms; Colorectal Neoplasms, He | 2020 |
Evaluation of implementation of risk management guidelines for carriers of pathogenic variants in mismatch repair genes: a nationwide audit of familial cancer clinics.
Topics: Adult; Anticarcinogenic Agents; Aspirin; Colonoscopy; Colorectal Neoplasms; Colorectal Neoplasms, He | 2020 |
57-Year-Old Woman With Weakness and Word-Finding Difficulties.
Topics: Adenocarcinoma, Clear Cell; Antibodies, Antiphospholipid; Aspirin; Biomarkers, Tumor; Cerebral Infar | 2021 |
57-Year-Old Woman With Weakness and Word-Finding Difficulties.
Topics: Adenocarcinoma, Clear Cell; Antibodies, Antiphospholipid; Aspirin; Biomarkers, Tumor; Cerebral Infar | 2021 |
Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium.
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Europe; Female; Follow-Up Studies; Hum | 2019 |
Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium.
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Europe; Female; Follow-Up Studies; Hum | 2019 |
Does aspirin have a role in management of ovarian cancer?
Topics: Analgesics; Aspirin; Cohort Studies; Female; Humans; Ovarian Neoplasms; Prognosis | 2018 |
Does aspirin have a role in management of ovarian cancer?
Topics: Analgesics; Aspirin; Cohort Studies; Female; Humans; Ovarian Neoplasms; Prognosis | 2018 |
Reduction of Cisplatin-Induced Ototoxicity without Compromising Its Antitumor Activity.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Aspirin; Cell Pr | 2018 |
Reduction of Cisplatin-Induced Ototoxicity without Compromising Its Antitumor Activity.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Aspirin; Cell Pr | 2018 |
Association of Analgesic Use With Risk of Ovarian Cancer in the Nurses' Health Studies.
Topics: Adult; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Ovarian Epithelial; | 2018 |
Association of Analgesic Use With Risk of Ovarian Cancer in the Nurses' Health Studies.
Topics: Adult; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Ovarian Epithelial; | 2018 |
Low-Dose Aspirin Use Associated with Lower Ovarian Cancer Risk.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; Female; Humans; | 2019 |
Low-Dose Aspirin Use Associated with Lower Ovarian Cancer Risk.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; Female; Humans; | 2019 |
An aspirin a day keeps ovarian cancer at bay?
Topics: Aspirin; Cyclooxygenase Inhibitors; Female; Humans; Ovarian Neoplasms | 2019 |
An aspirin a day keeps ovarian cancer at bay?
Topics: Aspirin; Cyclooxygenase Inhibitors; Female; Humans; Ovarian Neoplasms | 2019 |
Aspirin in prevention of ovarian cancer: are we at the tipping point?
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Carcinoma, | 2014 |
Aspirin in prevention of ovarian cancer: are we at the tipping point?
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Carcinoma, | 2014 |
Prevention: daily aspirin and chemoprevention.
Topics: Acetaminophen; Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticar | 2014 |
Prevention: daily aspirin and chemoprevention.
Topics: Acetaminophen; Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticar | 2014 |
Statins, aspirin and risk of thromboembolic events in ovarian cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Carcinoma, Ovarian Epithelial; | 2014 |
Statins, aspirin and risk of thromboembolic events in ovarian cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Carcinoma, Ovarian Epithelial; | 2014 |
Taking a daily aspirin might reduce ovarian cancer risk.
Topics: Aspirin; Case-Control Studies; Female; Humans; Ovarian Neoplasms | 2014 |
Taking a daily aspirin might reduce ovarian cancer risk.
Topics: Aspirin; Case-Control Studies; Female; Humans; Ovarian Neoplasms | 2014 |
Statistical Perspectives on Subgroup Analysis: Testing for Heterogeneity and Evaluating Error Rate for the Complementary Subgroup.
Topics: Algorithms; Antibiotics, Antineoplastic; Antineoplastic Agents; Aspirin; Clinical Trials as Topic; C | 2015 |
Statistical Perspectives on Subgroup Analysis: Testing for Heterogeneity and Evaluating Error Rate for the Complementary Subgroup.
Topics: Algorithms; Antibiotics, Antineoplastic; Antineoplastic Agents; Aspirin; Clinical Trials as Topic; C | 2015 |
Low-dose aspirin use and the risk of ovarian cancer in Denmark.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Anti-Inflammat | 2015 |
Low-dose aspirin use and the risk of ovarian cancer in Denmark.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Anti-Inflammat | 2015 |
Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, acetaminophen and ovarian cancer survival.
Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Middle Aged; | 2015 |
Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, acetaminophen and ovarian cancer survival.
Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Middle Aged; | 2015 |
Drugs with potential chemopreventive properties in relation to epithelial ovarian cancer--a nationwide case-control study.
Topics: Academic Dissertations as Topic; Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narc | 2015 |
Drugs with potential chemopreventive properties in relation to epithelial ovarian cancer--a nationwide case-control study.
Topics: Academic Dissertations as Topic; Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narc | 2015 |
How to assess the potential interest of aspirin in ovarian cancer?
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Ovarian Neoplasms | 2015 |
How to assess the potential interest of aspirin in ovarian cancer?
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Ovarian Neoplasms | 2015 |
Codelivery of SH-aspirin and curcumin by mPEG-PLGA nanoparticles enhanced antitumor activity by inducing mitochondrial apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Aspirin; Cell Line, Tumor; Curcumin; Drug Delivery Systems; Female | 2015 |
Codelivery of SH-aspirin and curcumin by mPEG-PLGA nanoparticles enhanced antitumor activity by inducing mitochondrial apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Aspirin; Cell Line, Tumor; Curcumin; Drug Delivery Systems; Female | 2015 |
Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion.
Topics: Adenosine Monophosphate; Aspirin; Blood Platelets; Cell Line, Tumor; Female; Flow Cytometry; Humans; | 2015 |
Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion.
Topics: Adenosine Monophosphate; Aspirin; Blood Platelets; Cell Line, Tumor; Female; Flow Cytometry; Humans; | 2015 |
CASE 11-2016 Perioperative Coronary Thrombosis in a Patient With Multiple Second-Generation Drug-Eluting Stents: Is It Time for a Paradigm Shift?
Topics: Analgesics, Opioid; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopid | 2016 |
CASE 11-2016 Perioperative Coronary Thrombosis in a Patient With Multiple Second-Generation Drug-Eluting Stents: Is It Time for a Paradigm Shift?
Topics: Analgesics, Opioid; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopid | 2016 |
Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Aspirin; Biomarkers; Cell Line, | 2016 |
Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Aspirin; Biomarkers; Cell Line, | 2016 |
Aspirin use and the incidence of breast, colon, ovarian, and pancreatic cancers in elderly women in the Iowa Women's Health Study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; | 2016 |
Aspirin use and the incidence of breast, colon, ovarian, and pancreatic cancers in elderly women in the Iowa Women's Health Study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; | 2016 |
Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention.
Topics: Aspirin; BRCA1 Protein; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Chemoprevention; Cyclooxyge | 2017 |
Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention.
Topics: Aspirin; BRCA1 Protein; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Chemoprevention; Cyclooxyge | 2017 |
Histone deacetylase inhibitors and aspirin interact synergistically to induce cell death in ovarian cancer cells.
Topics: Apoptosis; Aspirin; Cell Line, Tumor; Cyclooxygenase Inhibitors; Drug Synergism; Enzyme Inhibitors; | 2008 |
Histone deacetylase inhibitors and aspirin interact synergistically to induce cell death in ovarian cancer cells.
Topics: Apoptosis; Aspirin; Cell Line, Tumor; Cyclooxygenase Inhibitors; Drug Synergism; Enzyme Inhibitors; | 2008 |
VEGF expression and the effect of NSAIDs on ascites cell proliferation in the hen model of ovarian cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Ascites; Aspirin; Cell Growth Processes; Chickens; | 2008 |
VEGF expression and the effect of NSAIDs on ascites cell proliferation in the hen model of ovarian cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Ascites; Aspirin; Cell Growth Processes; Chickens; | 2008 |
Dietary aspirin decreases the stage of ovarian cancer in the hen.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chickens; Diet; Dinoprostone; Disease Mod | 2009 |
Dietary aspirin decreases the stage of ovarian cancer in the hen.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chickens; Diet; Dinoprostone; Disease Mod | 2009 |
Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts.
Topics: Acetaminophen; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Follow-Up Studies; H | 2009 |
Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts.
Topics: Acetaminophen; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Follow-Up Studies; H | 2009 |
Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer.
Topics: Animals; Apoptosis; Aspirin; Blotting, Western; Cell Line, Tumor; Cell Survival; Cyclooxygenase 2; C | 2010 |
Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer.
Topics: Animals; Apoptosis; Aspirin; Blotting, Western; Cell Line, Tumor; Cell Survival; Cyclooxygenase 2; C | 2010 |
The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21.
Topics: Aspirin; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinas | 2010 |
The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21.
Topics: Aspirin; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinas | 2010 |
A case of hypertension with virilisation during pregnancy.
Topics: Adult; Aspirin; Brenner Tumor; Calcium; Cesarean Section; Dehydroepiandrosterone Sulfate; Dietary Su | 2010 |
A case of hypertension with virilisation during pregnancy.
Topics: Adult; Aspirin; Brenner Tumor; Calcium; Cesarean Section; Dehydroepiandrosterone Sulfate; Dietary Su | 2010 |
[Antitumor effects of sulindac in ovarian cell cultures].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Cell Cycle; Cell Size; Cell | 2011 |
[Antitumor effects of sulindac in ovarian cell cultures].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Cell Cycle; Cell Size; Cell | 2011 |
Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or acetaminophen and risk of ovarian cancer.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Chi-Square Di | 2012 |
Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or acetaminophen and risk of ovarian cancer.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Chi-Square Di | 2012 |
Use of analgesic drugs and risk of ovarian cancer: results from a Danish case-control study.
Topics: Acetaminophen; Adult; Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Ag | 2012 |
Use of analgesic drugs and risk of ovarian cancer: results from a Danish case-control study.
Topics: Acetaminophen; Adult; Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Ag | 2012 |
Aspirin, other NSAIDs, and ovarian cancer risk (United States).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Confidence Intervals; Femal | 2002 |
Aspirin, other NSAIDs, and ovarian cancer risk (United States).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Confidence Intervals; Femal | 2002 |
Aspirin-induced inhibition of ovarian tumor cell growth.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Division; Dose-Response Relationship, Drug; F | 2002 |
Aspirin-induced inhibition of ovarian tumor cell growth.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Division; Dose-Response Relationship, Drug; F | 2002 |
Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor, NS398, in epithelial ovarian cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aspiri | 2003 |
Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor, NS398, in epithelial ovarian cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aspiri | 2003 |
The use of dimethylsulfoxide as a vehicle in cell culture experiments using ovarian carcinoma cell lines.
Topics: Acetaminophen; Aspirin; Cell Count; Cell Culture Techniques; Cell Division; Cell Line, Tumor; Cultur | 2003 |
The use of dimethylsulfoxide as a vehicle in cell culture experiments using ovarian carcinoma cell lines.
Topics: Acetaminophen; Aspirin; Cell Count; Cell Culture Techniques; Cell Division; Cell Line, Tumor; Cultur | 2003 |
Medication use and risk of ovarian carcinoma: a prospective study.
Topics: Acetaminophen; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Stu | 2004 |
Medication use and risk of ovarian carcinoma: a prospective study.
Topics: Acetaminophen; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Stu | 2004 |
Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis.
Topics: Adenomatous Polyposis Coli; Apoptosis; Aspirin; beta Catenin; Breast Neoplasms; Cell Nucleus; Colore | 2004 |
Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis.
Topics: Adenomatous Polyposis Coli; Apoptosis; Aspirin; beta Catenin; Breast Neoplasms; Cell Nucleus; Colore | 2004 |
Effects of aspirin on metastasis-associated gene expression detected by cDNA microarray.
Topics: Aspirin; Cyclooxygenase Inhibitors; Female; Gene Expression Profiling; Gene Expression Regulation, N | 2004 |
Effects of aspirin on metastasis-associated gene expression detected by cDNA microarray.
Topics: Aspirin; Cyclooxygenase Inhibitors; Female; Gene Expression Profiling; Gene Expression Regulation, N | 2004 |
Selective induction of cyclooxygenase-2 plays a role in lysophosphatidic acid regulated Fas ligand cell surface presentation.
Topics: Animals; Antigen Presentation; Antigens, Surface; Apoptosis; Aspirin; Cell Line, Tumor; Cell Membran | 2006 |
Selective induction of cyclooxygenase-2 plays a role in lysophosphatidic acid regulated Fas ligand cell surface presentation.
Topics: Animals; Antigen Presentation; Antigens, Surface; Apoptosis; Aspirin; Cell Line, Tumor; Cell Membran | 2006 |
Use of anti-thrombotic agents during chemotherapy for epithelial ovarian cancer.
Topics: Antineoplastic Agents; Aspirin; Drug Combinations; Female; Fibrinolytic Agents; Humans; Neoplasm Rec | 2006 |
Use of anti-thrombotic agents during chemotherapy for epithelial ovarian cancer.
Topics: Antineoplastic Agents; Aspirin; Drug Combinations; Female; Fibrinolytic Agents; Humans; Neoplasm Rec | 2006 |
Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Line, Tumor; Cell Proliferation; Cisplatin; D | 2006 |
Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Line, Tumor; Cell Proliferation; Cisplatin; D | 2006 |
Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Growth Processes; Cell Line, Tumor; | 2007 |
Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Growth Processes; Cell Line, Tumor; | 2007 |
[The growth inhibitory effect of non-steroid anti-inflammatory drugs on ovarian cancer].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Celecoxib; Cell Line, Tumor; C | 2007 |
[The growth inhibitory effect of non-steroid anti-inflammatory drugs on ovarian cancer].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Celecoxib; Cell Line, Tumor; C | 2007 |
Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Anti-Inflammatory Age | 2008 |
Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Anti-Inflammatory Age | 2008 |
Anti-tumor effect of non-steroidal anti-inflammatory drugs on human ovarian cancers.
Topics: Animals; Aspirin; Carcinoma; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Humans; | 2007 |
Anti-tumor effect of non-steroidal anti-inflammatory drugs on human ovarian cancers.
Topics: Animals; Aspirin; Carcinoma; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Humans; | 2007 |
NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts.
Topics: Animals; Aspirin; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Ne | 2008 |
NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts.
Topics: Animals; Aspirin; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Ne | 2008 |
NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols.
Topics: Animals; Antineoplastic Agents; Aspirin; Cell Line, Tumor; Cell Survival; Cisplatin; Dose-Response R | 2008 |
NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols.
Topics: Animals; Antineoplastic Agents; Aspirin; Cell Line, Tumor; Cell Survival; Cisplatin; Dose-Response R | 2008 |
Analgesic drug use and risk of epithelial ovarian cancer.
Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspir | 2008 |
Analgesic drug use and risk of epithelial ovarian cancer.
Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspir | 2008 |
Over-the-counter analgesics and risk of ovarian cancer.
Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspir | 1998 |
Over-the-counter analgesics and risk of ovarian cancer.
Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspir | 1998 |
Aspirin and ovarian cancer: an Italian case-control study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-C | 2000 |
Aspirin and ovarian cancer: an Italian case-control study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-C | 2000 |
Regular use of analgesic drugs and ovarian cancer risk.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cas | 2001 |
Regular use of analgesic drugs and ovarian cancer risk.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cas | 2001 |
Aspirin and epithelial ovarian cancer.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; Case-Control Studies; Fema | 2001 |
Aspirin and epithelial ovarian cancer.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; Case-Control Studies; Fema | 2001 |
Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Biopsy; Blotting, Wester | 2002 |
Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Biopsy; Blotting, Wester | 2002 |